InvestorsHub Logo
Followers 427
Posts 25995
Boards Moderated 6
Alias Born 09/26/2009

Re: None

Monday, 12/12/2022 8:39:17 AM

Monday, December 12, 2022 8:39:17 AM

Post# of 220
On December 12, 2022, Aptevo Therapeutics Inc. (“Aptevo” or the “Company”) announced that APVO436, in combination with venetoclax and azacytidine,
achieved a 100% clinical benefit rate in venetoclax treatment naïve AML patients. The data, which was presented in a poster session at the 64th American
Society of Hematology Annual Meeting and Exposition in New Orleans, also showed that APVO436, when given in combination with this standard-of-care
regimen, was observed to be generally safe and well tolerated.
Aptevo plans to initiate a Phase 2 trial in the second half of 2023 to further evaluate APVO436 in combination with venetoclax and azacitidine among frontline
and relapsed/refractory AML patients who are venetoclax treatment naïve.
Bullish
Bullish

Well that didn't go the way I expected

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APVO News